Clinical Trials

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

Novartis unveils groundbreaking Phase III data for Rhapsido, offering hope as the first potential targeted therapy for 29 million chronic hive sufferers.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

Relmada Therapeutics poaches a Sage neurosteroid expert for its sepranolone program. A look at the strategic rationale behind a move that signals big ambitions.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

One year in, the Facial Pain Registry has gathered data from 740 patients, creating an unprecedented resource to fight one of medicine's most misunderstood conditions.

Millions suffer from chronic sciatica with few good options. A small biotech is betting on a novel, non-opioid drug to fix the problem, not just mask it.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.